![]() In my personal, controversial opinion, TeXmacs is a child of the TeX community, not only because of its name. As for the more nebulous topics of what you should be doing with the software typography-wise, I'm sure such questions would be welcome on GraphicDesign.Īs always, read each site's help section to determine if your question is or is not on-topic before asking it there. Since it uses a Lisp for customization, I wouldn't be surprised to find some questions about customization on StackOverflow. ![]() So, where do these questions belong? TeXmacs is just another application after all, so questions about using it are on-topic for SuperUser. As such, texmacs should join mathjax as a tag-flag for off-topic questions. I come to the conclusion that texmacs is ultimately the same as mathjax: both of these technologies draw from the long history of TeX (whether to use familiar syntax or a familiar name), but neither actually involve TeX in any step of the process. While I don't personally like LyX questions here, at least they have the virtue of relying on TeX to get the job done. Repeating what's been said in the comments, TeXmacs ultimately uses a completely distinct typesetting engine that isn't TeX to produce its output. Robustness and consistency of this approach provides a solid basis for multi-center academic trials in the field of adoptive cell therapy.I'd put forth that TeXmacs should not be considered on-topic unless perhaps it's about its TeX export options (and even then, the idea leaves a bad taste in my mouth). Details of therapy and response are summarized in table 1.Ĭonclusion Production of CAR-T cells with the CliniMACS Prodigy TCT process is a feasible and an attractive option that provides a point-of-care manufacturing approach to enable rapid delivery of CAR-T cells to patients in need. In the patient with 74% blast in bone marrow at start of therapy, neither CAR-T cell expansion nor leukemia response were documented. In two cases with prominent mass lesions an objective response was documented. MRD-negative responses detected by flow cytometry and PCR were achieved in 2 cases with bone marrow involvement. In 3 cases CAR-T cell expansion was detected to a maximum 25%. All patients survived to the point of response evaluation. In one case additional dose of tocilizumab and one dose of dexamethasone were administered to control CRS and encephalopathy. In one case mild CAR-T cell related encephalopathy developed. In 2 cases mild cytokine release syndrome (CRS) was diagnosed. No immediate infusion reactions were reported. The cell products were administered at a dose of 1*10 6/kg of CAR-T cells. All final products passed the in-process and quality controls. CD4/CD8 ratio in the final product was 0,750,22-6). Median expansion of T cells was x26(24-43). Median transduction efficacy achieved was 57%(52-63). Results All production cycles were successful. All patients received prophylactic tocilizumab 1 hour before CAR-T cell infusion at 8mg/kg. Final product was administered without cryopreservation to the patients after fludarabine/cyclophosphamide preconditioning. Automatic production included CD4/CD8 selection, CD3/CD28 stimulation with MACS GMP T Cell TransAct, transduction with lentiviral (second generation CD19.4-1BB zeta) vector (Lentigen, Miltenyi Biotec company) and expansion over 12 days in the presence of TexMACS GMP Medium supplemented with MACS GMP IL-7/IL-15 combination. The CliniMACS Prodigy T cell transduction (TCT) process was used to produce CD19 CAR-T cells from patient-derived leukapheresis product. One patient had refractory primary mediastinal B-cell lymphoma (PMBCL). The patient with low minimal residual disease (MRD) in the bone marrow had skeletal involvement with multiple lymphomatous mass lesions. Bone marrow disease burden at therapy start was 12%, 74% and 0,159. Three patients, median age 15 years, had relapsed B-cell lineage acute lymphoblastic leukemia (B-ALL) after haploidentical hematopoietic stem cell transplantation (HSCT). Patients and methods Four patients with relapsed/refractory B-cell lineage malignancies were eligible for compassionate use of CD19 CAR-T cell therapy. We report on first cases of implementation of this approach in a setting of compassionate use program. ![]() An attractive model of CAR-T cell production and delivery to the patient is via a point-of care-manufacturing process. The predominant manufacturing model for this type of therapy is a centralized industrial-type production process. Introduction CD19 CAR-T cell products were recently approved as therapy for advanced B-cell lineage malignancies.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |